Unipol Gruppo Finanziario Spa (0Q6M)
London Exchange · UK · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 24.38 |
|---|---|
| 52-week range | 18.31 – 29.43 |
| Return, 1 month / 3 months | −7.0% / −5.6% |
| Return, 1 year / 3 years | +41.7% / +469.1% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 38 |
| Volatility (1 year) | 27.1% |
| Worst drawdown (1 year) | -14.4% |
| Average daily value traded | 1.99M EUR |
| Dividend yield | 4.6% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Unipol Gruppo Finanziario is an Italian insurance group based in Bologna. It offers non-life cover, with motor insurance as a core line, alongside life insurance and related financial services. Its customers are mainly households and small and medium-sized businesses in Italy, served through its insurance subsidiaries and agency networks. The group also holds interests in banking and real estate, which support its insurance business and broaden the financial services it provides to its policyholders and clients.
The shares are listed on the London Exchange in UK under the code 0Q6M, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 7 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Unipol Gruppo Finanziario Spa (0Q6M) trades on the London Exchange in UK. It last closed at EUR 24.38 on 23 October 2026.
Its price-based Market X-Ray is 70 out of 100 (a fair price profile), ranking 567 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 41.7% and over the last three months it fell 5.6%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 73 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 8.5% | ||
| From 52-week high | -16.8% | ||
| Momentum | 69 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -5.6% | ||
| 6-month return | 18.8% | ||
| 12-month return, skipping the last month | 52.4% | ||
| Stability (higher is calmer) | 79 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 27.1% | ||
| Worst drawdown, 1 year (smaller is calmer) | -14.4% | ||
| Liquidity | 60 · Fair | Moderate trading activity. | |
| Average daily value traded | 1.99M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 56 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 4.6% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | −4.5% |
|---|---|
| 1 month | −7.0% |
| 3 months | −5.6% |
| 6 months | +18.8% |
| 1 year | +41.7% |
| 3 years | +469.1% |
| 5 years | +565.2% |
Signals
| 50-day / 200-day average | 26.53 / 22.46 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.63 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 18 May 2026 | EUR 1.1200 |
| 19 May 2025 | EUR 0.8500 |
| 20 May 2024 | EUR 0.3800 |
| 22 May 2023 | EUR 0.3700 |
| 23 May 2022 | EUR 0.3000 |
| 18 Oct 2021 | EUR 0.2800 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.